Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2024-04-18

Clinical Trial Update: Natalizumab and Chronic Inflammation [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update for natalizumab in chronic inflammation (multiple sclerosis) has been terminated with results posted in 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Natalizumab (natalizumab)

Snippet

Sponsor: Vanderbilt University Medical Center | Conditions: Multiple Sclerosis | Phase 4 | Status: TERMINATED | Results posted: 2024-04-18